Diesel Exhaust and Vascular Function
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 49 |
| Updated: | 4/21/2016 |
| Start Date: | January 2012 |
| End Date: | December 2015 |
| Contact: | Karen Jansen, M.S. |
| Email: | cvd1trap@uw.edu |
| Phone: | 206-616-6525 |
Effect of Diesel Exhaust Exposures on Vascular Function in Humans: The Role of Sympathetic Activation
Double-blind, sham- and placebo-controlled randomized study of effects of freshly-generated
diluted diesel exhaust inhalation on vascular function. To examine role of adrenergic system
a trial of alpha-blocker terazosin is also used. Each participant completes four study
sessions, separated by at least three weeks: 1) Diesel exhaust inhalation (DE, controlled at
300 micrograms/cubic meter for two hours) and terazosin (2 mg prior to inhalation exposure);
2) DE plus placebo (matched for terazosin); 3) filtered air plus terazosin; and 4) filter
air plus placebo. The investigators assess outcomes of blood pressure, forearm brachial
artery ultrasound, and plasma measures of endothelial activation. The investigators
hypothesize that DE exposure will be associated with increased blood pressure, decreased
brachial artery diameter, and increased circulating endothelins, and that these effects will
be attenuated by terazosin administration.
diluted diesel exhaust inhalation on vascular function. To examine role of adrenergic system
a trial of alpha-blocker terazosin is also used. Each participant completes four study
sessions, separated by at least three weeks: 1) Diesel exhaust inhalation (DE, controlled at
300 micrograms/cubic meter for two hours) and terazosin (2 mg prior to inhalation exposure);
2) DE plus placebo (matched for terazosin); 3) filtered air plus terazosin; and 4) filter
air plus placebo. The investigators assess outcomes of blood pressure, forearm brachial
artery ultrasound, and plasma measures of endothelial activation. The investigators
hypothesize that DE exposure will be associated with increased blood pressure, decreased
brachial artery diameter, and increased circulating endothelins, and that these effects will
be attenuated by terazosin administration.
Inclusion Criteria:
- healthy without chronic illness
- Body Mass Index 18.5 - 26.0
- tolerates 2 mg terazosin dose without unacceptable symptoms
- able to return for four exposure sessions
Exclusion Criteria:
- any chronic disease
- tobacco user
- asthma
- elevated cholesterol
- obesity
- hypertension
- diabetes
- any chronic cardiovascular or pulmonary disease
- pregnancy or unwillingness to use effective contraception, if female
We found this trial at
1
site
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
Click here to add this to my saved trials
